We can summarize that simultaneous CD99 overexpression and reactivated cisplatin resistance in ovarian cancer cells suggest that CD99 can be an NRF2 downstream gene and that NRF2 can modulate cisplatin resistance by CD99 up or downregulation [74]. This evidence concerns the gene NFE2L2 and ovarian cancer.